Financials

v3.7.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2017
Dec. 31, 2016
Current Assets:    
Cash and cash equivalents $ 13,376 $ 19,055
Prepaid expenses and other current assets 1,540 2,515
Total Current Assets 14,916 21,570
Property and equipment, net 800 905
Deposits and other assets 24 23
Total Assets 15,740 22,498
Current Liabilities:    
Accounts payable 1,723 1,993
Accrued expenses 1,750 2,627
Warrant liabilities 7,573 14,821
Accrued employee benefits 1,209 313
Deferred rent 75 3
Total Current Liabilities 12,330 19,757
Long term deferred rent 448 492
Total Liabilities 12,778 20,249
Stockholders’ Equity:    
Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding 0 0
Common stock, $0.001 par value; 250,000,000 shares authorized, 127,827,578 issued and 127,746,096 outstanding and 117,254,196 issued and 117,172,714 outstanding 128 117
Additional paid-in capital 183,837 175,762
Accumulated deficit (179,135) (172,034)
Total Synthetic Biologics, Inc. and Subsidiaries Equity 4,830 3,845
Non-controlling interest (1,868) (1,596)
Total Stockholders' Equity 2,962 2,249
Total Liabilities and Stockholders' Equity $ 15,740 $ 22,498

Source

v3.7.0.1
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Operating Costs and Expenses:        
General and administrative $ 1,644 $ 2,147 $ 3,734 $ 4,573
Research and development 4,831 7,164 10,891 15,319
Total Operating Costs and Expenses 6,475 9,311 14,625 19,892
Loss from Operations (6,475) (9,311) (14,625) (19,892)
Other Income:        
Change in fair value of warrant liability 2,159 3,513 7,249 3,015
Interest income 1 34 3 35
Total Other Income 2,160 3,547 7,252 3,050
Net Loss (4,315) (5,764) (7,373) (16,842)
Net Loss Attributable to Non-controlling Interest (60) (82) (272) (315)
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries $ (4,255) $ (5,682) $ (7,101) $ (16,527)
Net Loss Per Share - Basic and Dilutive $ (0.03) $ (0.06) $ (0.06) $ (0.18)
Net Loss Per Share - Dilutive $ (0.03) $ (0.10) $ (0.06) $ (0.21)
Weighted average number of shares outstanding during the period - Basic 123,005,220 91,015,733 120,241,593 90,921,243
Weighted average number of shares outstanding during the period - Dilutive 123,005,220 93,930,540 120,241,593 92,651,215

Source

v3.7.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Cash Flows From Operating Activities:    
Net Loss $ (7,373) $ (16,842)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation 2,006 1,959
Change in fair value of warrant liabilities (7,249) (3,015)
Depreciation 116 57
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets 975 3,745
Deposits and other assets (1) (11)
Accounts payable (270) 143
Accrued expenses (877) 1,543
Accrued employee benefits 896 897
Deferred rent 29 (10)
Net Cash Used In Operating Activities (11,748) (11,534)
Cash Flows From Investing Activity:    
Purchases of property and equipment (11) (45)
Net Cash Used In Investing Activity (11) (45)
Cash Flows From Financing Activities:    
Proceeds from issuance of common stock for stock option exercises 166 810
Proceeds from “at the market” stock issuance 5,914 0
Net Cash Provided By Financing Activities 6,080 810
Net decrease in cash (5,679) (10,769)
Cash at beginning of period 19,055 20,818
Cash at end of period 13,376 10,049
Supplemental disclosures of cash flow information:    
Cash paid for interest 0 0
Cash paid for taxes $ 0 $ 0

Source